{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:39:47Z","timestamp":1778773187805,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T00:00:00Z","timestamp":1532736000000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation Global Health Program","doi-asserted-by":"publisher","award":["OPPGH5337"],"award-info":[{"award-number":["OPPGH5337"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ijantimicag.2017.01.038","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T03:01:47Z","timestamp":1495681307000},"page":"203-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis"],"prefix":"10.1016","volume":"50","author":[{"given":"Hollie","family":"Burrell-Saward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"de LaFlor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo S.","family":"Alavijeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-8649","authenticated-orcid":false,"given":"Theresa H.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-8006","authenticated-orcid":false,"given":"Simon L.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0010","first-page":"257","article-title":"Epidemiology of human African trypanosomiasis","volume":"6","author":"Franco","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1017\/S0031182012000169","article-title":"Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis","volume":"139","author":"Simarro","year":"2012","journal-title":"Parasitology"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0020","author":"Drugs for Neglected Diseases Initiative"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0025","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.pt.2014.08.002","article-title":"The lane to the brain: how African trypanosomes invade the CNS","volume":"30","author":"Mogk","year":"2014","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0030","author":"Drugs for Neglected Diseases Initiative"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0035","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0040","author":"Drugs for Neglected Diseases Initiative"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-014-0136-3","article-title":"Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies","volume":"53","author":"Tarral","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0050","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2014a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0055","doi-asserted-by":"crossref","first-page":"e2571","DOI":"10.1371\/journal.pntd.0002571","article-title":"Highly sensitive in vivo imaging of Trypanosoma brucei expressing \u2018red-shifted\u2019 luciferase","volume":"7","author":"McLatchie","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0060","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jac\/dku393","article-title":"A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis","volume":"70","author":"Burrell-Saward","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0070","first-page":"e54032","article-title":"Bioluminescence imaging to detect late stage infection of African trypanosomiasis","volume":"111","author":"Burrell-Saward","year":"2016","journal-title":"J Vis Exp"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0075","series-title":"The mouse brain in stereotaxic coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00213-003-1615-7","article-title":"Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: species and regional differences","volume":"172","author":"Hughes","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0024-3205(90)90043-Q","article-title":"Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro","volume":"46","author":"Bungay","year":"1990","journal-title":"Life Sci"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002384","article-title":"In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis","volume":"7","author":"Myburgh","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0095","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.00604-06","article-title":"Semimechanistic pharmacokinetic\/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments","volume":"51","author":"Nielsen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.48.2.369-377.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC","volume":"48","author":"Mueller","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0110","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1017\/S0031182009991806","article-title":"Trypanosomiasis and the brain","volume":"137","author":"Rodgers","year":"2010","journal-title":"Parasitology"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0115","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1128\/AAC.02754-13","article-title":"Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease","volume":"58","author":"Bahia","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.038_bib0120","doi-asserted-by":"crossref","first-page":"119re1","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci Transl Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:31:36Z","timestamp":1760376696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0924857917301693"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.038","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}